Mol Syst Biol:PDK4可作前列腺癌的独立预后标志物

2020-04-26 竹子 转化医学网

前列腺癌(PCa)是全世界男性中第二常见的癌症,也是第五大死于癌症的主要原因。

前列腺癌(PCa)是全世界男性中第二常见的癌症,也是第五大死于癌症的主要原因。PCa具有广泛的临床表现,因此迫切需要生物标志物来进行风险分层。如今,研究人员通过利用转录组学数据的基因共表达网络,以及从人和鼠前列腺石蜡包埋组织(FFPE)样品中提取的激光显微切割的蛋白质组学,找到了潜在的风险分层生物标志物。

统计数据表明,奥地利每年约有5,600名男性被诊断出患有前列腺癌,这意味着它约占男性所有癌症的四分之一。对于某些人来说,癌症发展缓慢并且需要最少的治疗,但是其他人则具有侵略性的疾病形式,并且进展很快。为了能够更有效地治疗前列腺癌,需要更好地理解在肿瘤分子水平上发生的复杂机制。在2015年,由维也纳医科大学的分子病理学家卢卡斯·肯纳(Lukas Kenner)领导的团队意外发现了STAT3蛋白在小鼠模型中在前列腺癌中起着抑癌作用。他们表明,与高水平的患者相比,癌细胞中STAT3水平低的患者的疾病进展显着恶化。

基于以前研究的发现,最近由维也纳医科大学病理学系肯纳团队的博士候选人莫妮卡·奥伯哈伯(Monika Oberhuber )与奥地利生物技术研究医学中心,COMET能力中心(由奥地利研究促进局(FFG)资助)共同进行了一项研究。研究发现,丙酮酸脱氢酶激酶4(PDK4)与STAT3蛋白有直接相关性,可将其基因表达作为前列腺癌的独立预后标志物,可预测前列腺癌复发与诊断风险因素。该研究发表在《分子系统生物学》期刊上。

该研究分析了许多大型患者数据集,并比较了组织中STAT3高表达和低表达的患者。这导致鉴定不同基因簇的表达特征之间的相关性。研究人员发现,STAT3低的患者的代谢活跃。代谢(尤其是细胞呼吸)在前列腺肿瘤中的活性比在健康前列腺组织中的活性高得多。这为肿瘤提供了额外的生长能量。STAT3低的患者表现出更高的细胞呼吸作用和更活跃的肿瘤,其中形成了许多新蛋白质。

奥伯哈伯还用石蜡包埋组织切片研究了低STAT3与活性代谢之间的关系。用激光显微镜将肿瘤组织与健康组织分离,然后使用质谱分析。

有趣的是,结果显示STAT3和PDK4之间存在直接相关性,从而减慢了细胞呼吸。显示STAT3低的患者也具有低PDK4,这可以证明PDK4直接受STAT3调节。这意味着PDK4水平可以很好地预测疾病的进程。换句话说,PDK4低的前列腺癌患者的预后要比PDK4高的前列腺癌患者差。PDK4基因在其他肿瘤和疾病(例如糖尿病)的发生中也起着重要作用。现在计划对PDK4进行后续研究,以研究其在前列腺癌治疗中的潜在应用。

原始出处:Monika Oberhuber, Matteo Pecoraro, Mate Rusz et al. STAT 3 ‐dependent analysis reveals PDK 4 as independent predictor of recurrence in prostate cancer. Molecular Systems Biology (2020).

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1820011, encodeId=8acd182001136, content=<a href='/topic/show?id=0b11100190a4' target=_blank style='color:#2F92EE;'>#预后标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100190, encryptionId=0b11100190a4, topicName=预后标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Sat Feb 06 12:02:17 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841508, encodeId=d227184150812, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat May 09 08:02:17 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767761, encodeId=f6991e67761b3, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Jan 10 01:02:17 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704849, encodeId=41151e048491a, content=<a href='/topic/show?id=f32e139595d' target=_blank style='color:#2F92EE;'>#PDK4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13959, encryptionId=f32e139595d, topicName=PDK4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06a30851040, createdName=ailian1212, createdTime=Fri Dec 04 07:02:17 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919064, encodeId=286a1919064ec, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jul 24 04:02:17 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542689, encodeId=7505154268946, content=<a href='/topic/show?id=3ef610019167' target=_blank style='color:#2F92EE;'>#预后标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100191, encryptionId=3ef610019167, topicName=预后标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24e13440329, createdName=ms7514935887898259, createdTime=Mon Apr 27 18:02:17 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040727, encodeId=86231040e2763, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 26 06:02:17 CST 2020, time=2020-04-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1820011, encodeId=8acd182001136, content=<a href='/topic/show?id=0b11100190a4' target=_blank style='color:#2F92EE;'>#预后标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100190, encryptionId=0b11100190a4, topicName=预后标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Sat Feb 06 12:02:17 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841508, encodeId=d227184150812, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat May 09 08:02:17 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767761, encodeId=f6991e67761b3, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Jan 10 01:02:17 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704849, encodeId=41151e048491a, content=<a href='/topic/show?id=f32e139595d' target=_blank style='color:#2F92EE;'>#PDK4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13959, encryptionId=f32e139595d, topicName=PDK4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06a30851040, createdName=ailian1212, createdTime=Fri Dec 04 07:02:17 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919064, encodeId=286a1919064ec, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jul 24 04:02:17 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542689, encodeId=7505154268946, content=<a href='/topic/show?id=3ef610019167' target=_blank style='color:#2F92EE;'>#预后标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100191, encryptionId=3ef610019167, topicName=预后标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24e13440329, createdName=ms7514935887898259, createdTime=Mon Apr 27 18:02:17 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040727, encodeId=86231040e2763, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 26 06:02:17 CST 2020, time=2020-04-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1820011, encodeId=8acd182001136, content=<a href='/topic/show?id=0b11100190a4' target=_blank style='color:#2F92EE;'>#预后标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100190, encryptionId=0b11100190a4, topicName=预后标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Sat Feb 06 12:02:17 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841508, encodeId=d227184150812, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat May 09 08:02:17 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767761, encodeId=f6991e67761b3, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Jan 10 01:02:17 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704849, encodeId=41151e048491a, content=<a href='/topic/show?id=f32e139595d' target=_blank style='color:#2F92EE;'>#PDK4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13959, encryptionId=f32e139595d, topicName=PDK4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06a30851040, createdName=ailian1212, createdTime=Fri Dec 04 07:02:17 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919064, encodeId=286a1919064ec, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jul 24 04:02:17 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542689, encodeId=7505154268946, content=<a href='/topic/show?id=3ef610019167' target=_blank style='color:#2F92EE;'>#预后标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100191, encryptionId=3ef610019167, topicName=预后标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24e13440329, createdName=ms7514935887898259, createdTime=Mon Apr 27 18:02:17 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040727, encodeId=86231040e2763, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 26 06:02:17 CST 2020, time=2020-04-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1820011, encodeId=8acd182001136, content=<a href='/topic/show?id=0b11100190a4' target=_blank style='color:#2F92EE;'>#预后标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100190, encryptionId=0b11100190a4, topicName=预后标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Sat Feb 06 12:02:17 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841508, encodeId=d227184150812, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat May 09 08:02:17 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767761, encodeId=f6991e67761b3, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Jan 10 01:02:17 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704849, encodeId=41151e048491a, content=<a href='/topic/show?id=f32e139595d' target=_blank style='color:#2F92EE;'>#PDK4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13959, encryptionId=f32e139595d, topicName=PDK4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06a30851040, createdName=ailian1212, createdTime=Fri Dec 04 07:02:17 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919064, encodeId=286a1919064ec, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jul 24 04:02:17 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542689, encodeId=7505154268946, content=<a href='/topic/show?id=3ef610019167' target=_blank style='color:#2F92EE;'>#预后标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100191, encryptionId=3ef610019167, topicName=预后标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24e13440329, createdName=ms7514935887898259, createdTime=Mon Apr 27 18:02:17 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040727, encodeId=86231040e2763, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 26 06:02:17 CST 2020, time=2020-04-26, status=1, ipAttribution=)]
    2020-12-04 ailian1212
  5. [GetPortalCommentsPageByObjectIdResponse(id=1820011, encodeId=8acd182001136, content=<a href='/topic/show?id=0b11100190a4' target=_blank style='color:#2F92EE;'>#预后标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100190, encryptionId=0b11100190a4, topicName=预后标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Sat Feb 06 12:02:17 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841508, encodeId=d227184150812, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat May 09 08:02:17 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767761, encodeId=f6991e67761b3, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Jan 10 01:02:17 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704849, encodeId=41151e048491a, content=<a href='/topic/show?id=f32e139595d' target=_blank style='color:#2F92EE;'>#PDK4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13959, encryptionId=f32e139595d, topicName=PDK4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06a30851040, createdName=ailian1212, createdTime=Fri Dec 04 07:02:17 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919064, encodeId=286a1919064ec, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jul 24 04:02:17 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542689, encodeId=7505154268946, content=<a href='/topic/show?id=3ef610019167' target=_blank style='color:#2F92EE;'>#预后标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100191, encryptionId=3ef610019167, topicName=预后标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24e13440329, createdName=ms7514935887898259, createdTime=Mon Apr 27 18:02:17 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040727, encodeId=86231040e2763, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 26 06:02:17 CST 2020, time=2020-04-26, status=1, ipAttribution=)]
    2020-07-24 sunylz
  6. [GetPortalCommentsPageByObjectIdResponse(id=1820011, encodeId=8acd182001136, content=<a href='/topic/show?id=0b11100190a4' target=_blank style='color:#2F92EE;'>#预后标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100190, encryptionId=0b11100190a4, topicName=预后标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Sat Feb 06 12:02:17 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841508, encodeId=d227184150812, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat May 09 08:02:17 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767761, encodeId=f6991e67761b3, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Jan 10 01:02:17 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704849, encodeId=41151e048491a, content=<a href='/topic/show?id=f32e139595d' target=_blank style='color:#2F92EE;'>#PDK4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13959, encryptionId=f32e139595d, topicName=PDK4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06a30851040, createdName=ailian1212, createdTime=Fri Dec 04 07:02:17 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919064, encodeId=286a1919064ec, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jul 24 04:02:17 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542689, encodeId=7505154268946, content=<a href='/topic/show?id=3ef610019167' target=_blank style='color:#2F92EE;'>#预后标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100191, encryptionId=3ef610019167, topicName=预后标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24e13440329, createdName=ms7514935887898259, createdTime=Mon Apr 27 18:02:17 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040727, encodeId=86231040e2763, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 26 06:02:17 CST 2020, time=2020-04-26, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1820011, encodeId=8acd182001136, content=<a href='/topic/show?id=0b11100190a4' target=_blank style='color:#2F92EE;'>#预后标志#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100190, encryptionId=0b11100190a4, topicName=预后标志)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6595338, createdName=xuruicheng, createdTime=Sat Feb 06 12:02:17 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841508, encodeId=d227184150812, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sat May 09 08:02:17 CST 2020, time=2020-05-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767761, encodeId=f6991e67761b3, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Jan 10 01:02:17 CST 2021, time=2021-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1704849, encodeId=41151e048491a, content=<a href='/topic/show?id=f32e139595d' target=_blank style='color:#2F92EE;'>#PDK4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13959, encryptionId=f32e139595d, topicName=PDK4)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c06a30851040, createdName=ailian1212, createdTime=Fri Dec 04 07:02:17 CST 2020, time=2020-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1919064, encodeId=286a1919064ec, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Fri Jul 24 04:02:17 CST 2020, time=2020-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542689, encodeId=7505154268946, content=<a href='/topic/show?id=3ef610019167' target=_blank style='color:#2F92EE;'>#预后标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100191, encryptionId=3ef610019167, topicName=预后标志物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b24e13440329, createdName=ms7514935887898259, createdTime=Mon Apr 27 18:02:17 CST 2020, time=2020-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040727, encodeId=86231040e2763, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sun Apr 26 06:02:17 CST 2020, time=2020-04-26, status=1, ipAttribution=)]
    2020-04-26 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Nat Med:多基因和临床风险评分及其对心脏代谢疾病和常见癌症发病年龄的影响和预测

多基因风险评分(PRSs)在预测常见疾病的易感性中表现出了良好的前景。

Nat Commun:前列腺特异性抗原动态能够预测个体对间歇性雄激素阻断治疗的个体响应

间歇性雄激素阻断治疗(IADT)是生化复发前列腺癌(PCa)的一种很有吸引力的治疗方法,并且循环的断断续续治疗能够减少累计剂量并限制毒性。

J Exp Clin Cancer Res:MAZ通过转录激活KRas依赖性的RalGEFs通路促进前列腺癌骨转移

临床上,前列腺癌(PCa)表现出高度的骨转移倾向性。Myc-associated zinc-finger protein (MAZ)是一种有文献记载的肿瘤基因,参与多种癌症类型的进展和转移,甚至在PC

Med Sci Monit:KIF18A的表达与前列腺癌的肿瘤分期和细胞增殖相关

KIF18A在肿瘤发生和肿瘤发展中的作用已经在几种癌症中得到了很好的研究,但在前列腺癌中没有。在本研究中,我们研究了KIF18A的潜在预后效用及其在前列腺癌进展中的作用。

BMC Cancer:根治性前列腺切除术后高危PSA复发的前列腺癌的抢救性放疗加安慰剂与SRT加恩扎鲁胺的II期随机双盲对照研究

在前列腺癌根治性切除术后PSA升高的男性中,抢救性放射治疗(SRT)提供了第二次治愈机会。激素治疗可以与SRT结合使用,以增加对前列腺肿瘤的控制,尽管伴随有更高的治疗副作用率。本试验研究了SRT与激素